Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Why Achillion Pharmaceuticals Shares Soared in October

16,904 views

Published on

Johnson & Johnson's decision to launch a mid stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.
In the following slideshow, I outline what iyou need to know about this trial and why it matters to Achillion Pharmaceuticals investors.

Published in: Healthcare, Health & Medicine
  • Instantly Hard-Wire Your Mind For Millionaire SUCCESS  https://tinyurl.com/y44vwbuh
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • ..............ACCESS that WEBSITE Over for All Ebooks ................ ......................................................................................................................... DOWNLOAD FULL PDF EBOOK here { https://urlzs.com/UABbn } ......................................................................................................................... Download Full EPUB Ebook here { https://urlzs.com/UABbn } .........................................................................................................................
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Earn a 6-Figure Side-Income Online... Signup for the free training HERE ◆◆◆ https://tinyurl.com/y3ylrovq
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Download The Complete Lean Belly Breakthrough Program with Special Discount. ▲▲▲ http://ishbv.com/bkfitness3/pdf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • How can I sharpen my memory? How can I improve forgetfulness? find out more... ♥♥♥ https://tinyurl.com/brainpill101
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Why Achillion Pharmaceuticals Shares Soared in October

  1. 1. Why Achillion Pharmaceuticals Shares Soared in October
  2. 2. What: Achillion Pharmaceuticals is a clinical stage biotech researching hepatitis C treatment. • Odalasvir (ACH-3102) is an NS5A inhibitor. • ACH-3422 is a nucleotide NS5B inhibitor. • Sovaprevir is a protease inhibitor. Shares jumped 13.2% in October. • Co-developer Johnson & Johnson outlines plans for mid stage studies that include Achillion’s lead candidate. .
  3. 3. Achillion Pharmaceuticals
  4. 4. So What: Hepatitis C is a major market indication affecting millions of people globally. • ~3 million people in the United States. • ~9 million people in Europe. • ~1.5 million people in Japan. • Up to 170 million people worldwide.
  5. 5. So What:
  6. 6. So What: Johnson & Johnson is positioning its HCV therapy as a short duration, best-in-class solution. •Mid stage study to begin soon. • Evaluates J&J’s Olysio and AL-335, plus Achillion’s ACH-3102. • Studying safety and efficacy over four-, six-, and eight-week treatment durations.
  7. 7. Now what: Hepatitis C treatment is a multi-billion dollar market. • Top therapies annual sales run rate of >$22 billion exiting Q3.
  8. 8. Now what continued: •Increasingly competitive marketplace. • Merck FDA decision date for its HCV therapy on January 28. • Gilead Sciences application of its next-generation pan-genotype HCV therapy submitted in October 2015. • AbbVie FDA application for once-daily dosing of Viekira Pak submitted in October 2015.
  9. 9. Now what continued: •Future battle for market share to focus on short duration therapies with 95% plus cure rates. •No guarantee that J&J’s trials will succeed. •Data from phase 2 expected in 2016. •If successful and approved, Achillion will receive milestones and royalties. • Development, sales, and regulatory milestones of $1.1 billion. • Tiered royalties from mid-teens to low 20% range.
  10. 10. Now what continued: Achillion Pharmaceuticals is a high-risk company without any products on the market. • Big potential market. • Potentially shortest duration HCV therapy if approved. • Significant trial and commercialization experience via J&J. • Suitable for risk-tolerant investors able to withstand a clinical trial failure.
  11. 11. This iSecret stock could make Achillion’s pop look tiny.

×